SCHEMBL30009231

SCHEMBL30009231

CC1C=CCN(C(=O)c2ccnc(F)c2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
PLA2G7 Q13093 1/20 0.40
PROKR1 Q8TCW9 8/20 0.38
GAA P10253 1/20 0.38
MGLL Q99685 1/20 0.37
NPC1 O15118 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PREP P48147 1/20 0.36
FAP Q12884 1/20 0.36
TLR9 Q9NR96 1/20 0.36
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
ABL1 P00519 1/20 0.36
BCR P11274 1/20 0.36
PDE4B Q07343 1/20 0.35
PDE4D Q08499 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009093 0.85 GAA (0.38) PLA2G7PROKR1GAANPC1HSD17B10
SCHEMBL30009435 0.84 PROKR1 (0.49) TAS1R3TAS1R1TAS1R2PROKR1GAA
SCHEMBL30009418 0.84 JAK1 (0.45) PROKR1HSD17B10ABL1BCR
SCHEMBL30009910 0.74 JAK1 (0.40) PLA2G7PROKR1GAANPC1HSD17B10
SCHEMBL30009325 0.73 HPGD (0.66) GAANPC1HSD17B10
SCHEMBL30009295 0.73 JAK1 (0.43) GAANPC1PREPFAP
SCHEMBL34462844 0.72 CHRNB2 (0.41) TAS1R3TAS1R1TAS1R2PROKR1GAA
SCHEMBL34463093 0.72 HPGD (0.58)
SCHEMBL34463038 0.71 PDK2 (0.49) TAS1R3TAS1R1TAS1R2PROKR1NPC1
SCHEMBL34462951 0.71 PDK2 (0.49) TAS1R3TAS1R1TAS1R2PROKR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 TAS1R3 3513/4885TAS1R1 3121/4885TAS1R2 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.